 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"What clinical data is there regarding inflammatory markers and antidiabetic agents ?"Dr. Steven V. Edelman (biography)
English - 2004-06-04 - 12 minutes
|
 | (7 slides) |
Summary :
Dr. Edelman presents data showing the reduction in inflammatory markers with metformin and thiazolidinediones (TZDs).
The Diabetes Prevention Program (DPP) showed the lowering of C-reactive protein (CRP) with metformin. A study by Satoh et al. showed the lowering of CRP with pioglitazone not only in responders but non-responders as well, suggesting an anti-inflammatory effect of the drug independent of its glucose-lowering effects. In data presented at the 64th ADA meeting of June 2004, Weissman et al. showed that early addition of rosiglitazone to 1g metformin caused reductions in CRP, matrix metalloproteinase 9 (MMP-9) as well as plasminogen activator inhibitor-1 (PAI-1).
More information is available about C-Reactive Protein.
Copyright © 2004 E-MedHosting.com Inc.
Learning objectives :
After viewing these slides the participant will be able to discuss:
- The effects of lifestyle intervention and metformin on CRP (DPP Study)
- The effect of pioglitazone on plasma CRP levels in responders and non-responders
- The reduction of inflammatory markers with early addition of rosiglitazone to 1g metformin
Bibliographic references :
Neelima V. Chu, MD, Alice P. S. Kong, MRCP, Dennis D. Kim, MD, Debra Armstrong, RN, Sunita Baxi, MD, Reena Deutsch, PHD, Michael Caulfield, PHD, Sunder R. Mudaliar, MD, MRCP, Richard Reitz, MD, Robert R. Henry, MD, FRCP and Peter D. Reaven, MD.Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Diabetes Care.2002; 25:542-549.
Dmitri Kirpichnikov, MD; Samy I. McFarlane, MD; and James R. Sowers, MD.Metformin: An Update Ann Int Med.2002;137(1):25-33.
Noriko Satoh, MD, PHD, Yoshihiro Ogawa, MD, PHD, Takeshi Usui, MD, PHD, Tetsuya Tagami, MD, PHD, Shigeo Kono, MD, PHD, Hiroko Uesugi, MD, PHD, Hiroyuki Sugiyama, MD, PHD, Akira Sugawara, MD, PHD, Kazunori Yamada, MD, PHD, Akira Shimatsu, MD, PHD, Hideshi Kuzuya, MD, PHD and Kazuwa Nakao, MD, PHD.Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect Diabetes Care.2003; 26:2493-2499.
PETER N. WEISSMAN, BARRY J. GOLDSTEIN, JOHN C. CAMPBELL, ERROL M. GOULD, BRIAN R. WATERHOUSE, LEANNE J. STROW, ALEXANDER R. COBITZ.Rosiglitazone Plus Metformin Combination Effects on CV Risk Markers Suggest Potential CV Benefits in Type 2 Diabetic Patients ADA 64th Scientific Sessions Abstract 121-OR.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
